id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-283380-l60yyr6l	Grabbe, Stephan	Systemic immunosuppression in times of COVID‐19: Do we need to rethink our standards?	2020-08-02		.txt	text/plain	2577	123	35	However, it is also currently under discussion whether patients under immunosuppressive therapy also have a higher risk of suffering a severe course of the COVID-19 disease. However, in clinical practice, long-term therapeutic use of hydroxychloroquine in patients with systemic lupus erythematosus does not appear to protect against covid-19 disease or a severe course of the disease [30, 31] . Therefore, the authors recommend that this therapy option should be considered especially in patients with other risk factors for a severe course of SARS-CoV-2 infection. Essentially, there is currently no data available for a general reduction or pause of immunosuppression in patients with autoimmune diseases, since the risk of an insufficient therapy of these mostly severe diseases is clearly higher than that of an aggravated course of COVID-19 disease. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial	./cache/cord-283380-l60yyr6l.txt	./txt/cord-283380-l60yyr6l.txt